Drug Database
Back to search

France· FR:61038695

BREYANZI 1,1 à 70 × 1 000 000 cellules/ml / 1,1 à 70 × 1 000 000 cellules/ml, dispersion pour perfusion

A lisocabtagene maraleucel product containing lisocabtagène maraleucel, registered in France by BRISTOL-MYERS SQUIBB PHARMA (IRLANDE). The same ATC class is registered in 12 of our 19 countries.

ATC L01XL08

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedBREYANZI 1,1 à 70 × 1 000 000 cellule…ATCL01XL08REGISTER NO.FR:61038695PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lisocabtagène maraleucelAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lisocabtagene maraleucel is registered in 12 of 19 countries.

Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose
Search lisocabtagene maraleucel products by name

Lisocabtagene maraleucel · ATC L01XL08

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
LISOCABTAGÈNE MARALEUCEL
Manufacturer
BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
Country
France (FR)
ATC code
L01XL08
ATC class
Lisocabtagene maraleucel
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955089537
    1 à 4 flacons copolymère de cyclooléfines de 4,6 ml de chaque composant cellulaire

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

37 interactions on record for lisocabtagene maraleucel.

Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lisocabtagene maraleucel against other medicinesHow interaction checks work

Lisocabtagene maraleucel · interactions on record

37 records

  • 21 severe
  • 16 moderate

Most severe, free to view

  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • LeflunomidL04AA13severe
  • NatalizumabL04AA23severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lisocabtagene maraleucel in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lisocabtagene maraleucel products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Breyanzi
  • Liechtenstein · Breyanzi
  • Norway · Breyanzi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/41048466-c465-4608-98d2-1b7806c5fefe
GET /v1/drugs/41048466-c465-4608-98d2-1b7806c5fefe?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61038695",
  "date_amm": "2022-04-04",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/22/1631",
  "substance": "LISOCABTAGÈNE MARALEUCEL",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "dispersion et  dispersion pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about lisocabtagene maraleucel.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console